Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
07:05am, Wednesday, 01'st Apr 2026
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 31'st Mar 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously ap
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI's 2026 Performance
08:15am, Sunday, 29'th Mar 2026
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size.
Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?
12:31pm, Friday, 27'th Mar 2026
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
SRPT Stock Surges on Promising Early Results From siRNA Programs
02:15pm, Thursday, 26'th Mar 2026
Sarepta Therapeutics shares surge 35% as early data from two siRNA therapies show strong target knockdown, safety and muscle delivery potential.
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?
10:01am, Thursday, 26'th Mar 2026
Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be mor
Sarepta Therapeutics Target of Unusually Large Options Trading (NASDAQ:SRPT)
02:44am, Thursday, 26'th Mar 2026
Sarepta Therapeutics, Inc. (NASDAQ: SRPT - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Investors acquired 6,110 call options on the company. This is an in
Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1 Transcript
05:35pm, Wednesday, 25'th Mar 2026
Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1 Transcript
Sarepta Therapeutics' experimental siRNA therapies show promising early results
11:39am, Wednesday, 25'th Mar 2026
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares surged almost 26% to about $22 after the biotechnology company shared early clinical results from two of its investigational siRNA therapies for neuromusc
Why Is Sarepta Therapeutics Stock Exploding Today?
11:17am, Wednesday, 25'th Mar 2026
Sarepta Therapeutics recently shared the first clinical results from its siRNA programs, specifically SRP-1001 and SRP-1003, which are designed to treat facioscapulohumeral muscular dystrophy (FSHD1)
The VIX Crashes Out, For Now, on Hope For Peace and Cheaper Oil
10:02am, Wednesday, 25'th Mar 2026
The fear gauge pulled back on Wednesday. The CBOE Volatility Index, better known as the VIX, is trading near 25.6 this morning, a drop of roughly 5% from Tuesday's close of 26.95, as geopolitical opti
Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?
09:44am, Wednesday, 25'th Mar 2026
Sarepta Therapeutics (NASDAQ:SRPT) stock is up approximately 20% in early trading on Wednesday after the company released its first-ever clinical data from two siRNA programs targeting rare neuromuscu
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
08:05am, Wednesday, 25'th Mar 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared the first clinical results from two of its siRNA p
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
04:05pm, Tuesday, 24'th Mar 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Easter
2 Beaten-Down Stocks That Still Aren't Worth Buying
04:00pm, Saturday, 21'st Mar 2026
These two companies are facing nearly insurmountable challenges. Their share prices could keep on dropping over the medium term.
